Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | TACR2 | P21452 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210000 | 0.91 | HSD11B1 (0.35) | HSD11B1LTA4HRXRARXRBCMA1 | |
| SCHEMBL208579 | 0.91 | HSD11B1 (0.35) | HSD11B1LTA4HRXRARXRBCMA1 | |
| SCHEMBL15204257 | 0.90 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL208568 | 0.87 | SRD5A2 (0.33) | LTA4HTACR2TACR1TACR3CMA1 | |
| SCHEMBL15204195 | 0.83 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL209204 | 0.83 | PDE4B (0.37) | HSD11B1 | |
| SCHEMBL209206 | 0.83 | PDE4B (0.37) | HSD11B1 | |
| SCHEMBL209999 | 0.82 | PDE4B (0.37) | HSD11B1 | |
| SCHEMBL210001 | 0.82 | PDE4B (0.37) | HSD11B1 | |
| SCHEMBL209306 | 0.82 | HSD11B1 (0.51) | HSD11B1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016047-B1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | claimed |
| US-8088776-B2 | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2012-01-03 | — | — | US | claimed |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | claimed |
| EP-2016047-B1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885LTA4H 533/4885TACR2 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.